Zevra Therapeutics (STU:1GDA) Stock Based Compensation: €11.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1GDA Zevra Therapeutics Inc STU:1GDA
69 GF Score
Price €9.80
GF Value €17.92
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zevra Therapeutics Stock Based Compensation?

Zevra Therapeutics STU:1GDA +0.82% 69 Stock Based Compensation is €11.3 Mil as of Jun. 2026. GuruFocus rates STU:1GDA with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Possible Value Trap). The stock has 5 warning signs investors should review.

Zevra Therapeutics's Stock Based Compensation for the three months ended in Jun. 2026 was €2.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was €11.3 Mil.

Zevra Therapeutics Stock Based Compensation Related Terms

Zevra Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Zevra Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zevra Therapeutics Stock Based Compensation Chart

Zevra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.16 4.05 5.46 14.24 10.79

Zevra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 2.36 3.66 2.69 2.58
STU:1GDA
69GF Score
Zevra Therapeutics Inc STU:1GDA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zevra Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.3 Mil.

What does a Stock Based Compensation of €11.3 Mil mean?
Zevra Therapeutics (STU:1GDA) has a Stock Based Compensation of €11.3 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zevra Therapeutics and its competitors.
Is Zevra Therapeutics' Stock Based Compensation too high?
Zevra Therapeutics' current Stock Based Compensation is €11.3 Mil. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Stock Based Compensation compare to TECX and RLMD?
Zevra Therapeutics' Stock Based Compensation of €11.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Zevra Therapeutics and its competitors. Zevra Therapeutics's current Stock Based Compensation is €11.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current Stock Based Compensation is €11.3 Mil. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current Stock Based Compensation is €11.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?

Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued. The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92. GuruFocus considers Zevra Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1GDA:

  • Stock Based Compensation: €11.3 Mil
  • GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zevra Therapeutics Business Description

Other Exchanges ZVRA:USA
Address 101 Federal Street, Boston, MA, USA, 02110
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score

Get the complete analysis for STU:1GDA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.80
Price
€17.92
GF Value